Clinical trial
Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of…
NCT00494234 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00494234 |
|---|---|
| Title | Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer |
| Official title | A Phase II, Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU-0059436 Given Orally Twice Daily in Patients With Advanced BRCA1- or BRCA2-associated Breast Cancer. |
| Acronym | ICEBERG 1 |
| Lead sponsor | AstraZeneca, Industry |
| Collaborators | KuDOS Pharmaceuticals Limited Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | Olaparib |
| Enrollment | 54 |
| Start date | Jun 15, 2007 |
| Primary completion | Feb 27, 2009 |
| Completion | Dec 21, 2022 |
| First posted | Jun 29, 2007 |
| Last update posted | Jan 19, 2024 |
| Countries | Australia, Canada, Germany, Israel, Spain, Sweden, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: